GPX4 and renal cell adenocarcinoma: Researchers suggest that future studies could explore NRF2 activity inhibitors applicable to humans or develop inhibitors targeting succinated GPX4 to induce ferroptosis in hereditary leiomyomatosis and renal cell cancer cells.